Key result
Elevated depressive symptoms linked to steeper HbA1c and glucose increases among those with low executive function.
Why the study?
Depressive symptoms and executive functions are novel risk factors for type 2 diabetes, but whether they interact to influence diabetes pathophysiology across the life span is unknown.
Do depressive symptoms and executive functions interactively influence longitudinal trajectories of diabetes biomarkers in adults without diabetes?
Cohort (n=1,257)
Do depressive symptoms and executive functions interactively influence longitudinal trajectories of diabetes biomarkers in adults without diabetes?
Effect estimate: b = -0.0001 (glycated hemoglobin); b = -0.0004 (fasting serum glucose)
p-value: p=0.005 (glycated hemoglobin); <0.001 (fasting serum glucose)
Elevated depressive symptoms combined with lower executive functions are associated with steeper age-related increases in diabetes biomarkers, identifying a high-risk group for earlier diabetes incidence.
Depressive symptoms may flag faster glycemic rise in low-executive-function adults; leaves open whether interventions alter diabetes risk.
Objective Depressive symptoms and executive functions (EFs) have recently emerged as novel risk factors for type 2 diabetes, but it is unknown if these factors interact to influence diabetes pathophysiology across the life span. We examined the synergistic associations of depressive symptoms and EFs with longitudinal trajectories of diabetes diagnostic criteria among middle-aged and older adults without diabetes. Methods Participants were 1257 African American and White, urban-dwelling adults from the Healthy Aging in Neighborhoods of Diversity across the Life Span study who were assessed up to three times over a 13-year period (2004–2017). At baseline, participants completed the Center for Epidemiological Studies—Depression scale and measures of EFs—Trail Making Test Part B, verbal fluency, and Digit Span Backward—for a composite EFs score, and provided blood samples at each follow-up for glycated hemoglobin and fasting serum glucose. Results A total of 155 and 220 individuals developed diabetes or prediabetes at wave 3 and wave 4, respectively. Linear mixed-effects regression models adjusting for sociodemographic factors, diabetes risk factors, and antidepressant medications revealed significant three-way interactions of Center for Epidemiological Studies—Depression, EFs, and age on change in glycated hemoglobin (b = −0.0001, p = .005) and in fasting serum glucose (b = −0.0004, p < .001), such that among individuals with lower but not higher EFs, elevated depressive symptoms were associated with steeper age-related increases in diabetes biomarkers over time. Conclusions Depressive symptoms and lower EFs may interactively accelerate trajectories of key diagnostic criteria, thereby increasing the risk for earlier diabetes incidence. Identifying individuals in this high-risk group may be an important clinical priority for earlier intervention, which has the promise of preventing or delaying this debilitating disease.
No takes yet. Share an insight, caveat, or question.
Khambaty et al. (2022) conducted a cohort in Diabetes risk (n=1,257). Depressive symptoms and executive functions was evaluated on change in glycated hemoglobin and fasting serum glucose (b = -0.0001 (glycated hemoglobin); b = -0.0004 (fasting serum glucose), p=0.005 (glycated hemoglobin); <0.001 (fasting serum glucose)). Among individuals with lower executive functions, elevated depressive symptoms were associated with steeper age-related increases in glycated hemoglobin (p=0.005) and fasting serum glucose (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: